Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5360)
All Articles published online
|
Publishing Process of This Article
|
Apr 15, 2022 (publication date) through May 13, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xu YJ, Zhang P, Hu JL, Liang H, Zhu YY, Cui Y, Niu P, Xu M, Liu MY. Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness. World J Gastrointest Oncol 2022; 14(4): 920-934 [PMID: 35582108 DOI: 10.4251/wjgo.v14.i4.920] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i4/920.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
An-Sofie Vander Mijnsbrugge, Justine Cerckel, Iris Dirven, Jens Tijtgat, Manon Vounckx, Nele Claes, Bart Neyns. Regorafenib in patients with pretreated advanced melanoma: a single-center case series. Melanoma Research 2024; 34(4): 366 doi: 10.1097/CMR.0000000000000977
|
| 3 |
Dan Wang, Hui Sun, Kerong Hai, Ningkang Li, Yang Gu, Zengrui Ma. Propofol alleviates traumatic brain injury through regulating Th17/Treg balance by activation of the AMPK/SIRT1 pathway. Toxicology Mechanisms and Methods 2025; : 1 doi: 10.1080/15376516.2025.2481893
|
| 4 |
Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang. Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy. Current Treatment Options in Oncology 2025; 26(3): 213 doi: 10.1007/s11864-025-01306-8
|
| 5 |
Ji Li, Jin-Xian Zhu, Yu-Xin Zhang, Shi-Qiang Li. Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis. Oncology Letters 2024; 27(4) doi: 10.3892/ol.2024.14286
|
| 6 |
Hang Yu, Qingquan Liu, Keting Wu, Shuang Tang. Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis. Clinical and Experimental Medicine 2024; 24(1) doi: 10.1007/s10238-024-01408-x
|
| 7 |
Qing Wu, Ziming Wang, Yang Luo, Xianhe Xie. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients. BMC Immunology 2023; 24(1) doi: 10.1186/s12865-023-00564-1
|